SMT202000506T1 - Metodi per preparare derivati benzodiazepinici citotossici - Google Patents

Metodi per preparare derivati benzodiazepinici citotossici

Info

Publication number
SMT202000506T1
SMT202000506T1 SM20200506T SMT202000506T SMT202000506T1 SM T202000506 T1 SMT202000506 T1 SM T202000506T1 SM 20200506 T SM20200506 T SM 20200506T SM T202000506 T SMT202000506 T SM T202000506T SM T202000506 T1 SMT202000506 T1 SM T202000506T1
Authority
SM
San Marino
Prior art keywords
methods
benzodiazepine derivatives
cytotoxic benzodiazepine
preparing cytotoxic
preparing
Prior art date
Application number
SM20200506T
Other languages
English (en)
Italian (it)
Inventor
Baudouin Gérard
Manami Shizuka
Michael Louis Miller
Richard A Silva
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SMT202000506T1 publication Critical patent/SMT202000506T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
SM20200506T 2015-07-21 2016-07-21 Metodi per preparare derivati benzodiazepinici citotossici SMT202000506T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562195023P 2015-07-21 2015-07-21
US201662327973P 2016-04-26 2016-04-26
PCT/US2016/043414 WO2017015502A1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives
EP16745598.9A EP3325482B1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
SMT202000506T1 true SMT202000506T1 (it) 2020-11-10

Family

ID=56557925

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20200506T SMT202000506T1 (it) 2015-07-21 2016-07-21 Metodi per preparare derivati benzodiazepinici citotossici
SM20200004T SMT202000004T1 (it) 2015-07-21 2016-07-21 Metodi di preparazione dei derivati citotossici di benzodiazepina

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20200004T SMT202000004T1 (it) 2015-07-21 2016-07-21 Metodi di preparazione dei derivati citotossici di benzodiazepina

Country Status (23)

Country Link
US (11) US9873708B2 (enExample)
EP (7) EP3653628B1 (enExample)
JP (8) JP2018522018A (enExample)
KR (5) KR20240055903A (enExample)
CN (5) CN108055844A (enExample)
AU (7) AU2016297608B2 (enExample)
CA (4) CA2992082A1 (enExample)
CY (2) CY1122553T1 (enExample)
DK (2) DK3325482T3 (enExample)
ES (4) ES2820358T3 (enExample)
HK (1) HK1252322A1 (enExample)
HR (1) HRP20201479T1 (enExample)
HU (1) HUE051541T2 (enExample)
IL (10) IL283355B (enExample)
LT (2) LT3325483T (enExample)
PL (2) PL3325482T3 (enExample)
PT (2) PT3325482T (enExample)
RS (2) RS59806B1 (enExample)
RU (3) RU2018105752A (enExample)
SG (2) SG10202009354SA (enExample)
SI (2) SI3325482T1 (enExample)
SM (2) SMT202000506T1 (enExample)
WO (3) WO2017015495A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283355B (en) 2015-07-21 2022-08-01 Immunogen Inc Methods for the preparation of cytotoxic benzodiazepine compounds
CN118099069A (zh) 2016-03-22 2024-05-28 Ev 集团 E·索尔纳有限责任公司 用于衬底的接合的装置和方法
WO2018075692A2 (en) 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
KR102312222B1 (ko) 2016-12-22 2021-10-12 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체
CN116554262A (zh) 2017-01-25 2023-08-08 伊缪诺金公司 制备细胞毒性苯二氮䓬衍生物的方法
US12152064B2 (en) 2018-06-05 2024-11-26 King's College London and GammaDelta Therapeutics Limited BTNL3/8 targeting constructs for delivery of payloads
AU2019379104A1 (en) * 2018-11-12 2021-06-03 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
US10913713B2 (en) * 2018-11-12 2021-02-09 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
EP3947395A1 (en) * 2019-03-29 2022-02-09 ImmunoGen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763183A (en) 1972-07-10 1973-10-02 Sterling Drug Inc 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines
US3860600A (en) 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
US4678784A (en) 1984-04-11 1987-07-07 Mcneilab, Inc. Method for the treatment of LHRH diseases and conditions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
DE69907977T2 (de) 1998-08-27 2004-07-22 Spirogen Ltd., Ryde Pyrrolobenzodiazepine
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
JP2003514903A (ja) 1999-11-24 2003-04-22 イムノージェン インコーポレーテッド タキサンを含有する細胞傷害薬とその治療への利用
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
AU2003247587B2 (en) 2002-08-02 2009-07-09 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
RU2314309C2 (ru) 2003-03-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
WO2004087716A1 (en) 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research Pyrrolo[(2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
CA2520898C (en) 2003-03-31 2009-10-20 Council Of Scientific And Industrial Research Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof
RU2338747C2 (ru) 2003-03-31 2008-11-20 Каунсил Оф Сайентифик Энд Индастриал Рисерч ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2543318C (en) 2003-10-22 2013-01-08 B. Rao Vishnuvajjala Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
JP4520411B2 (ja) 2003-12-31 2010-08-04 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン・ハイブリッドの調製方法
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
ATE542821T1 (de) * 2004-03-01 2012-02-15 Spirogen Ltd 11-hydroxy-5h-pyrroloä2,1-cüä1,4übenzodiazepin- - on derivate als zwischenverbindungen für die herstellung von c2 substituierten pyrrolobenzodiazepinen
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
GB0412492D0 (en) * 2004-06-04 2004-07-07 Sterix Ltd Compound
GB2439881C (en) 2005-04-21 2011-08-10 Spirogen Ltd Pyrrolobenzodiazepines
GB0508084D0 (en) * 2005-04-21 2005-06-01 Spirogen Ltd Pyrrolobenzodiazepines
DE602006006199D1 (de) 2005-10-05 2009-05-20 Spirogen Ltd 4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
US7763731B2 (en) * 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
JP2009526778A (ja) 2006-02-13 2009-07-23 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 抗腫瘍剤としてのビス−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−アントラキノン抱合体およびその製造方法
PL2032606T3 (pl) 2006-05-30 2014-04-30 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowania
ES2435779T3 (es) 2007-07-19 2013-12-23 Sanofi Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
ATE543826T1 (de) 2007-08-01 2012-02-15 Council Scient Ind Res Als selektive antitumormittel geeignete pyrroloä2,1-cüä1,4übenzodiazepinglycosid-prodru s
MX2010011808A (es) 2008-04-30 2011-03-04 Immunogen Inc Conjugados potentes y enlazadores hidrofilicos.
KR20210005318A (ko) 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0822260D0 (en) * 2008-12-05 2009-01-14 Merten Christoph Assay
KR101172638B1 (ko) * 2008-12-30 2012-08-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
IL295601B2 (en) 2009-02-05 2024-11-01 Immunogen Inc Benzodiazepine Derivatives and Processes for Producing the Same
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
WO2011071078A1 (ja) * 2009-12-08 2011-06-16 国立大学法人岐阜大学 芳香族化合物、並びに、それを用いたオリゴヌクレオチド誘導体合成用修飾担体、オリゴヌクレオチド誘導体及びオリゴヌクレオチド構築物
US8962279B2 (en) * 2009-12-30 2015-02-24 Intel Corporation Solid-phase chelators and electronic biosensors
ES2730763T3 (es) * 2010-02-11 2019-11-12 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
MY171234A (en) 2010-02-24 2019-10-04 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
MX2012011900A (es) 2010-04-15 2013-03-21 Seattle Genetics Inc Conjugados de pirrolobenzodiazepina diana.
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
WO2012112687A1 (en) 2011-02-15 2012-08-23 Immunogen, Inc. Methods of preparation of conjugates
CN102234253B (zh) * 2011-06-02 2013-07-03 重庆莱美药业股份有限公司 一种制备非布索坦中间体的方法
HK1211208A1 (zh) * 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
CA3188691A1 (en) * 2013-10-04 2015-04-09 Novartis Ag 3'end caps for rnai agents for use in rna interference
CN104628772A (zh) 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
CN103664896B (zh) * 2013-11-25 2016-03-02 济南精合医药科技有限公司 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
EP3778601A1 (en) * 2014-09-03 2021-02-17 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
RU2017110068A (ru) 2014-09-03 2018-10-03 Иммуноджен, Инк. Конъюгаты, содержащие клеточносвязывающие агенты и цитотоксические агенты
IL283355B (en) 2015-07-21 2022-08-01 Immunogen Inc Methods for the preparation of cytotoxic benzodiazepine compounds
ES2970186T3 (es) * 2015-11-25 2024-05-27 Immunogen Inc Formulaciones farmacéuticas y métodos de uso de las mismas

Also Published As

Publication number Publication date
IL256854A (en) 2018-03-29
CA2991326A1 (en) 2017-01-26
ES2959741T3 (es) 2024-02-28
RU2018105752A3 (enExample) 2019-12-30
EP3325482B1 (en) 2020-06-24
US10081640B2 (en) 2018-09-25
US20230257400A1 (en) 2023-08-17
CN108290895A (zh) 2018-07-17
AU2016297087A1 (en) 2018-02-08
US9890179B2 (en) 2018-02-13
PL3325483T3 (pl) 2020-05-18
AU2016297087B2 (en) 2021-02-18
PT3325482T (pt) 2020-09-24
WO2017015502A1 (en) 2017-01-26
JP2018524387A (ja) 2018-08-30
JP2023162264A (ja) 2023-11-08
JP2022046542A (ja) 2022-03-23
IL305989A (en) 2023-11-01
DK3325482T3 (da) 2020-09-28
IL286788B1 (en) 2023-09-01
IL283355A (en) 2021-07-29
AU2016297608B2 (en) 2021-02-18
CA2991305A1 (en) 2017-01-26
SI3325482T1 (sl) 2020-11-30
RU2018105609A (ru) 2019-08-26
CY1122553T1 (el) 2021-01-27
RU2727151C2 (ru) 2020-07-21
RU2018105756A3 (enExample) 2019-12-23
IL286788A (en) 2021-10-31
EP4286387A3 (en) 2024-02-21
IL294651A (en) 2022-09-01
US20210171547A1 (en) 2021-06-10
WO2017015502A8 (en) 2017-03-02
EP3325485B1 (en) 2020-04-08
AU2016297608A1 (en) 2018-02-08
CN113087763A (zh) 2021-07-09
JP2023166434A (ja) 2023-11-21
ES2764548T3 (es) 2020-06-03
AU2021202403A1 (en) 2021-05-20
JP6858745B2 (ja) 2021-04-14
JP2021035958A (ja) 2021-03-04
US20170050985A1 (en) 2017-02-23
US9873708B2 (en) 2018-01-23
IL276631A (en) 2020-09-30
IL256860B (en) 2020-08-31
JP7334228B2 (ja) 2023-08-28
EP3653628A1 (en) 2020-05-20
CN108055844A (zh) 2018-05-18
IL294651B1 (en) 2023-10-01
PL3325482T3 (pl) 2021-01-11
EP4163284A1 (en) 2023-04-12
IL256860A (en) 2018-03-29
IL305279A (en) 2023-10-01
HRP20201479T1 (hr) 2020-12-11
IL294651B2 (en) 2024-02-01
EP3653628B1 (en) 2022-09-14
LT3325483T (lt) 2020-01-27
JP6995178B2 (ja) 2022-02-21
KR102659706B1 (ko) 2024-04-23
JP7337114B2 (ja) 2023-09-01
US11420982B2 (en) 2022-08-23
IL276631B (en) 2021-10-31
AU2021203148A1 (en) 2021-06-10
AU2021202403B2 (en) 2022-12-08
CN108290895B (zh) 2021-03-19
US10899775B2 (en) 2021-01-26
SMT202000004T1 (it) 2020-03-13
WO2017015496A1 (en) 2017-01-26
JP2018526340A (ja) 2018-09-13
EP3325483B1 (en) 2019-10-02
IL276630A (en) 2020-09-30
KR20240055903A (ko) 2024-04-29
RS60840B1 (sr) 2020-10-30
HK1252322A1 (zh) 2019-05-24
EP3325483A1 (en) 2018-05-30
CA3227588A1 (en) 2017-01-26
KR20240055894A (ko) 2024-04-29
US20190010169A1 (en) 2019-01-10
EP3778602A1 (en) 2021-02-17
KR20180038460A (ko) 2018-04-16
KR20180038461A (ko) 2018-04-16
IL256861B (en) 2020-08-31
EP4286387A2 (en) 2023-12-06
EP3778602B1 (en) 2023-07-12
CA2991305C (en) 2024-03-12
IL286788B2 (en) 2024-01-01
IL256861A (en) 2018-03-29
US20170050986A1 (en) 2017-02-23
PT3325483T (pt) 2020-01-15
RU2746322C2 (ru) 2021-04-12
AU2016297607A1 (en) 2018-02-08
CY1123390T1 (el) 2022-03-24
SI3325483T1 (sl) 2020-03-31
ES2933376T3 (es) 2023-02-06
HK1252321A1 (en) 2019-05-24
RU2018105756A (ru) 2019-08-21
DK3325483T3 (da) 2020-01-20
WO2017015495A1 (en) 2017-01-26
JP2018522018A (ja) 2018-08-09
CN113004288A (zh) 2021-06-22
JP6787995B2 (ja) 2020-11-18
IL276630B (en) 2021-06-30
RU2018105609A3 (enExample) 2020-04-30
EP3325485A1 (en) 2018-05-30
AU2023202221A1 (en) 2023-05-04
CN108026103B (zh) 2021-04-16
US20200017526A1 (en) 2020-01-16
US20190389883A1 (en) 2019-12-26
ES2820358T3 (es) 2021-04-20
JP2021100959A (ja) 2021-07-08
AU2021203148B2 (en) 2023-01-12
SG10202106529XA (en) 2021-07-29
EP3325482A1 (en) 2018-05-30
RS59806B1 (sr) 2020-02-28
HUE051541T2 (hu) 2021-03-01
IL283355B (en) 2022-08-01
US20170051011A1 (en) 2017-02-23
US10392407B2 (en) 2019-08-27
US20190112320A1 (en) 2019-04-18
US20210171546A1 (en) 2021-06-10
US10787463B2 (en) 2020-09-29
AU2023201339A1 (en) 2023-04-06
US20180201626A1 (en) 2018-07-19
SG10202009354SA (en) 2020-11-27
KR102660070B1 (ko) 2024-04-24
RU2018105752A (ru) 2019-08-21
US10370389B2 (en) 2019-08-06
KR20180026741A (ko) 2018-03-13
CA2992082A1 (en) 2017-01-26
HK1252323A1 (en) 2019-05-24
CN108026103A (zh) 2018-05-11
LT3325482T (lt) 2020-11-25

Similar Documents

Publication Publication Date Title
IL291598A (en) History of benzodiazepine cytotoxicity
IL286788B1 (en) Methods for the preparation of cytotoxic benzodiazepine compounds
SG11201706729SA (en) Derivatives of sobetirome
SMT202100551T1 (it) Derivati di sobetirome
IL287405A (en) Methods for preparing cytotoxic benzodiazepine derivatives
IL293192A (en) Methods for the preparation of indolinobenzodiazepine derivatives
IL283047A (en) Methods for preparing cytotoxic benzodiazepine derivatives
SG11202104360YA (en) Methods of preparing cytotoxic benzodiazepine derivatives
GB201414116D0 (en) Benzodiazepine derivatives
GB201513979D0 (en) Synthesis of benzodiazepine derivatives
HUP1400545A2 (hu) Eljárás benzazepin származékok elõállítására
HK1236934A1 (zh) 细胞毒性苯并二氮呯衍生物